Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Opiant Pharmaceuticals (OPNT) stock

Learn how to easily invest in Opiant Pharmaceuticals stock.

Opiant Pharmaceuticals, Inc
NASDAQ: OPNT - USD
BIOTECHNOLOGY
$17.41
+$0.62 (+3.69%)

Opiant Pharmaceuticals, Inc is a biotechnology business based in the US. Opiant Pharmaceuticals shares (OPNT) are listed on the NASDAQ and all prices are listed in US Dollars. Opiant Pharmaceuticals employs 30 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Opiant Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – OPNT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Opiant Pharmaceuticals stock price (NASDAQ: OPNT)

Use our graph to track the performance of OPNT stocks over time.

Opiant Pharmaceuticals shares at a glance

Information last updated 2021-07-23.
Latest market close$12.65
52-week range$6.79 - $18.98
50-day moving average $14.49
200-day moving average $12.31
Wall St. target price$41.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $1.79

Buy Opiant Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Opiant Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Opiant Pharmaceuticals price performance over time

Historical closes compared with the close of $12.65 from 2021-05-28

1 week (2021-07-13) N/A
1 month (2021-06-24) -7.80%
3 months (2021-04-20) N/A
6 months (2021-01-20) N/A
1 year (2020-07-20) N/A
2 years (2019-07-20) N/A
3 years (2018-07-20) N/A
5 years (2016-07-20) N/A

Is Opiant Pharmaceuticals under- or over-valued?

Valuing Opiant Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Opiant Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Opiant Pharmaceuticals's EBITDA

Opiant Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $9.5 million.

The EBITDA is a measure of a Opiant Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Opiant Pharmaceuticals financials

Revenue TTM $31.7 million
Gross profit TTM $14.2 million
Return on assets TTM -3.66%
Return on equity TTM -8.91%
Profit margin -9.52%
Book value $7.85
Market capitalisation $72.7 million

TTM: trailing 12 months

Shorting Opiant Pharmaceuticals shares

There are currently 13,449 Opiant Pharmaceuticals shares held short by investors – that's known as Opiant Pharmaceuticals's "short interest". This figure is 8% down from 14,621 last month.

There are a few different ways that this level of interest in shorting Opiant Pharmaceuticals shares can be evaluated.

Opiant Pharmaceuticals's "short interest ratio" (SIR)

Opiant Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Opiant Pharmaceuticals shares currently shorted divided by the average quantity of Opiant Pharmaceuticals shares traded daily (recently around 17932). Opiant Pharmaceuticals's SIR currently stands at 0.75. In other words for every 100,000 Opiant Pharmaceuticals shares traded daily on the market, roughly 750 shares are currently held short.

However Opiant Pharmaceuticals's short interest can also be evaluated against the total number of Opiant Pharmaceuticals shares, or, against the total number of tradable Opiant Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Opiant Pharmaceuticals's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Opiant Pharmaceuticals shares in existence, roughly 0 shares are currently held short) or 0.0035% of the tradable shares (for every 100,000 tradable Opiant Pharmaceuticals shares, roughly 4 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Opiant Pharmaceuticals.

Find out more about how you can short Opiant Pharmaceuticals stock.

Opiant Pharmaceuticals share dividends

We're not expecting Opiant Pharmaceuticals to pay a dividend over the next 12 months.

Have Opiant Pharmaceuticals's shares ever split?

Opiant Pharmaceuticals's shares were split on a 1:100 basis on 30 December 2014. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Opiant Pharmaceuticals shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Opiant Pharmaceuticals shares which in turn could have impacted Opiant Pharmaceuticals's share price.

Opiant Pharmaceuticals share price volatility

Over the last 12 months, Opiant Pharmaceuticals's shares have ranged in value from as little as $6.7878 up to $18.98. A popular way to gauge a stock's volatility is its "beta".

OPNT.US volatility(beta: 0.72)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Opiant Pharmaceuticals's is 0.7236. This would suggest that Opiant Pharmaceuticals's shares are less volatile than average (for this exchange).

Opiant Pharmaceuticals overview

Opiant Pharmaceuticals, Inc. , a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016.

Frequently asked questions

What percentage of Opiant Pharmaceuticals is owned by insiders or institutions?
Currently 6.628% of Opiant Pharmaceuticals shares are held by insiders and 24.143% by institutions.
How many people work for Opiant Pharmaceuticals?
Latest data suggests 30 work at Opiant Pharmaceuticals.
When does the fiscal year end for Opiant Pharmaceuticals?
Opiant Pharmaceuticals's fiscal year ends in July.
Where is Opiant Pharmaceuticals based?
Opiant Pharmaceuticals's address is: 233 Wilshirre Boulevard, Santa Monica, CA, United States, 90401
What is Opiant Pharmaceuticals's ISIN number?
Opiant Pharmaceuticals's international securities identification number is: US6837501039
What is Opiant Pharmaceuticals's CUSIP number?
Opiant Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 53224T105

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site